In the first five months of 2024, there was a surge in high-value deals, though none have yet matched the scale of Pfizer’s $43 billion acquisition of Seagen, which closed in December 2023. With Novo Holdings’ $16.5 billion purchase of Catalent leading the pack, 2024 reflects a mixed but strong trend toward sizable M&A…
The 100 best-funded biotech companies from 2015 to present
In early 2022, secretive Altos Labs emerged with a sizable $3 billion launch to pursue anti-aging “cellular rejuvenation” amid rumors of Jeff Bezos’ backing. The company is the best-funded biotech in recent memory. But looking back to 2015 to present, the best funded company is Grail, which developed a multi-cancer early detection test but faced major…
Here’s where the biotech funding is going in 2023 and 2024
Over the past year, North American biotech firms continued to lear the world in funding by a significant margin in an analysis that included a various equity fundraising types drawn from Crunchbase. Argenx, a publicly traded Dutch biotech, raised $1.1 billion from investors in July 2023 through a global offering. Next in line was…
Moderna leans on RSV vaccine, AI and a diversified pipeline to regain competitive edge
Moderna surged to prominence thanks to its rapid development of a competitive COVID-19 vaccine. Since the early days of the pandemic, however, the company has struggled to maintain its momentum. Year-to-date, its stock is down close to 40%, trading around $110 per share. Adapting to COVID-19 variants The company hopes that its development of vaccines…